Shorepower Technologies, Inc. has entered into a merger agreement with Aeternum Health LLC that will fundamentally transform the company's strategic direction from transportation infrastructure to longevity-focused healthcare. The transaction represents a complete corporate overhaul, with the company issuing 51% ownership to Aeternum Health's sole member and receiving in return intellectual property, cash, and business assets centered on peptide technology for anti-aging applications. The merger agreement, dated February 17, 2026, will see Aeternum Health merge into Shorepower, with Shorepower continuing as the surviving entity.
As part of the transaction, the company will receive transfer of know-how and data relating to a novel peptide mix in development for longevity and anti-aging, together with associated intellectual property. Aeternum Health will also contribute a minimum of $1.5 million in cash and a business related to commercialization of the peptide technology. Leadership changes accompany the strategic shift, with Jeff Kim resigning as President, CEO, and sole director. Paul E. Mann, Manager of Aeternum Health, will assume all three positions upon closing of the merger. Mann brings extensive biotechnology and healthcare investment experience, having previously served in senior roles at Soros Fund Management and Highbridge Capital, and currently serving as Chairman and CEO of ASP Isotopes Inc. (Nasdaq: ASPI).
The transaction includes several corporate actions that signal the comprehensive nature of the transformation. The company plans to change its name to Aeternum Health Inc., increase authorized common shares to 250 million, and spin out its existing transportation electrification business. This legacy business currently designs, manufactures, and operates transportation electrification equipment including systems for truck stops and electric vehicle supply equipment. Financial aspects of the deal include issuance of 2,000,000 shares of Series B Preferred Stock, each share having voting power equal to 40 shares of common stock.
The parties intend for the merger to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code. Financial statements and pro forma financial information relating to Aeternum Health will be filed by amendment within 71 calendar days of the initial Form 8-K filing available through regulatory channels. This strategic pivot comes as longevity and anti-aging technologies gain increasing attention in both scientific and investment communities. The transaction represents one of the more dramatic corporate transformations in recent memory, moving a company from the transportation sector directly into the competitive biotechnology and healthcare optimization space. The success of this transition will depend on multiple factors including regulatory approvals, integration of the peptide technology, and market acceptance of the new strategic direction.
